Blennow K - Search Results

1

Matrix metalloproteinases are associated with brain atrophy in cognitively unimpaired individuals.

Aksnes M, Capogna E, Vidal-Piñeiro D, Chaudhry FA, Myrstad M, Idland AV, Halaas NB, Dakhil S, Blennow K, Zetterberg H, Walhovd KB, Watne LO, Fjell AM. Aksnes M, et al. Among authors: blennow k. Neurobiol Aging. 2023 Nov;131:11-23. doi: 10.1016/j.neurobiolaging.2023.05.012. Epub 2023 May 29. Neurobiol Aging. 2023. PMID: 37549446 Free article.

2

Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease.

Sjögren M, Minthon L, Passant U, Blennow K, Wallin A. Sjögren M, et al. Among authors: blennow k. Neurobiol Aging. 1998 Sep-Oct;19(5):379-84. doi: 10.1016/s0197-4580(98)00086-4. Neurobiol Aging. 1998. PMID: 9880039

3

Cerebrospinal fluid markers for prediction of Alzheimer's disease.

Zetterberg H, Wahlund LO, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurosci Lett. 2003 Nov 27;352(1):67-9. doi: 10.1016/j.neulet.2003.08.011. Neurosci Lett. 2003. PMID: 14615052

4

Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.

Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Johansson A, et al. Among authors: blennow k. Hum Genet. 2004 May;114(6):581-7. doi: 10.1007/s00439-004-1107-9. Epub 2004 Mar 18. Hum Genet. 2004. PMID: 15034781

5

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. Prince JA, et al. Among authors: blennow k. Neurology. 2004 Jun 8;62(11):2116-8. doi: 10.1212/01.wnl.0000128088.08695.05. Neurology. 2004. PMID: 15184629

6

Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.

Zetterberg H, Andreasen N, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurosci Lett. 2004 Sep 2;367(2):194-6. doi: 10.1016/j.neulet.2004.06.001. Neurosci Lett. 2004. PMID: 15331151

7

Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results.

Zetterberg H, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurol Sci. 2004 Dec;25(5):301-2. doi: 10.1007/s10072-004-0358-5. Neurol Sci. 2004. PMID: 15624089 No abstract available.

8

Evaluation of factors of importance for clinical dementia diagnosis.

Nagga K, Garcia J, Zetterberg H, Blennow K, Gottfries J, Marcusson J. Nagga K, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2005;19(5-6):289-98. doi: 10.1159/000084554. Epub 2005 Mar 18. Dement Geriatr Cogn Disord. 2005. PMID: 15775718 Free article.

9

Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease.

Johansson A, Zetterberg H, Hampel H, Buerger K, Prince JA, Minthon L, Wahlund LO, Blennow K. Johansson A, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2005;20(6):367-74. doi: 10.1159/000088634. Epub 2005 Sep 29. Dement Geriatr Cogn Disord. 2005. PMID: 16192727

10

Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease.

Blennow K, Johansson A, Zetterberg H. Blennow K, et al. Int J Mol Med. 2005 Dec;16(6):1147-9. Int J Mol Med. 2005. PMID: 16273298

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,184 results

Search Page

Filters